Petlife Pharmaceuticals (OTCPK:PTLF) - Stock Price, News & Analysis

PTLF Stock Overview

Engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. More details

PTLF fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($22K)

Shares are highly illiquid

Petlife Pharmaceuticals, Inc. Competitors

Lucy Scientific Discovery

OTCPK:LSDI.F

US$8.8k

Hero Technologies

OTCPK:HENC

US$563.0

CBD Life Sciences

OTCPK:CBDL

US$1.4m

Veritas Farms

OTCPK:VFRM

US$81.9k

Price History & Performance

Summary of all time highs, changes and price drops for Petlife Pharmaceuticals
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0002
52 Week Low	US$0.0001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	0%
5 Year Change	-96.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PTLF	US Pharmaceuticals	US Market
7D	0%	2.6%	0.5%
1Y	n/a	13.1%	30.7%

Return vs Industry: Insufficient data to determine how PTLF performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how PTLF performed against the US Market.

Price Volatility

Is PTLF's price volatile compared to industry and market?
PTLF volatility
PTLF Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PTLF's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PTLF's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Sebastian Serrell-Watts	n/a

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company’s principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor.

Petlife Pharmaceuticals, Inc. Fundamentals Summary

How do Petlife Pharmaceuticals's earnings and revenue compare to its market cap?
PTLF fundamental statistics
Market cap	US$22.21k
Earnings (TTM)	-US$3.71m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is PTLF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTLF income statement (TTM)
Revenue	US$0
Cost of Revenue	US$17.92k
Gross Profit	-US$17.91k
Other Expenses	US$3.69m
Earnings	-US$3.71m

Last Reported Earnings

Feb 28, 2018

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PTLF perform over the long term?

See historical performance and comparison